Compare Incyte Corporation (INCY) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.05. The key difference: Incyte Corporation is trading nearer its 52-week high, SP Funds S&P 500 Sharia Industry Exclusions ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SPUS | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $59.51 |
52-Week Low | $67.38 | $45.32 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SPUS trades at $56.32, down 0.23% on the day, with a neutral technical signal overall. The stock shows bullish moving average alignment but oscillators indicate indecision. Recent dividends of $0.03 per share were distributed in April, May, and June 2026, reflecting a stable income component. Key support lies at $56, with resistance near $57.
Outlook remains balanced; dividend consistency supports income investors, but limited fundamental data and neutral technicals suggest cautious optimism. Risks include market volatility and reliance on broader dividend strategy performance. Upside depends on sustained dividend growth and favorable market conditions for income-focused equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
